Posters

      Influence Of Sub-Chronic Cigarette Smoke Exposure On The Progression Of Myocardial Hypertrophy In Spontaneously Hypertensive Rats (SHR)

      von Holt, K.; K-Schlüter, K-D. Schlüter.; Ruf, S.; Meurrens, K.; Schleef, R.
      Conference date
      Mar 6, 2005
      Conference name

      Society of Toxicology (SOT) 2005
      Link to more information
      Topic
      Summary

      In search of an experimental model for cardiac risk by smoking we exposed 8-week old male SHR to cigarette mainstream smoke (MS) from the Kentucky reference cigarette 2R4F (450 µg total particulate matter/l) or to fresh air (sham) for 30, 60, and 90 days (2 hours/day, 5 days/week) to investigate the development of myocardial hypertrophy (heart/body weight ratio, mRNA expression of hypertrophy markers via real-time RT-PCR, and protein expression via immunoblots). Basal heart function was determined in vitro by Langendorff-perfusion. Blood pressure and heart rate were monitored in vivo via telemetric analysis. Due to a reduced increase in body weight, the MS groups had an approximately 20% larger increase in heart/body weight ratio after just 30 days (5.83 ± 0.29 versus 4.94 ± 0.35 mg/g; p<0.01) accompanied by elevated basal heart function (left ventricular developed pressure: 103.9 ± 5.9 vs. 83.3 ± 6.5 mm hg, p<0.01). The mRNA expression of myocardial hypertrophy markers, i.e., atrial natriuretic factor, ornithine decarboxylase, and TGF-β, increased in both ventricles (more pronounced at 90 days than at 30 days). In the sham groups these markers were less increased in the left ventricle and did not change over time in the right ventricle. Increases in ANF and TGF-β were confirmed on the protein level in the 90-day MS group. There were no measurable differences for blood pressure or heart rate between MS and sham groups. The mRNA expression for calcium-handling proteins (SERCA2a and NCX) did not change. At the same time, there was less p-adrenergic response in heart function to isoprenaline (100 nm). SHR exposed to MS showed a faster progression of myocardial hypertrophy with a reduction in β-adrenergic response. This effect is independent of hypertension and occurs in both ventricles. The data suggest the acceleration of cardiac dysfunction development by sub-chronic MS exposure in rats.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.